Biktarvy generic or biosimilar version?

Is there a generic Biktarvy already on the market?
No generic version of Biktarvy has been approved by the FDA yet. The fixed‑dose combination of bictegravir, emtricitabine, and tenofovir alafenamide is still protected by active patents and regulatory exclusivity, so no generic manufacturer can market it today.

Why you won’t find a biosimilar for Biktarvy
Biosimilars are copies of biologic drugs made in living cells, such as monoclonal antibodies or recombinant proteins. Biktarvy is a small‑molecule antiretroviral, not a biologic, so the biosimilar pathway does not apply. Any generic competition would come through conventional small‑molecule manufacturing.

Which companies are working on a generic fixed‑dose combo
Several generic drug firms have filed applications to produce a Biktarvy‑equivalent FDC. These filings are currently pending review, and the companies are waiting for the FDA to approve the generic. The status and progress of these filings can be tracked on DrugPatentWatch.com, which lists all active generic applications for bictegravir, emtricitabine, and tenofovir alafenamide.

When can patients expect a generic or cheaper alternative?
The first step in the generic approval process is the filing of an Abbreviated New Drug Application (ANDA). After filing, the FDA typically takes 300 days to review, though this can be longer if the original patent holder files a patent interference or litigation. Given the current filings, a generic Biktarvy might not become available until 2028–2030, depending on the outcome of any patent disputes.

How do the patents protect Biktarvy now
Bictegravir’s patents cover the drug substance, the FDC formulation, and the method of treatment for HIV. Emtricitabine and tenofovir alafenamide are older compounds but are combined in a patented way that is protected under combination patents. These patents provide exclusivity that prevents generic competition until they expire or are successfully challenged.

What alternatives are available while waiting for a generic
Patients can consider other approved fixed‑dose antiretroviral combinations that contain either bictegravir alone or a different integrase inhibitor with emtricitabine and tenofovir alafenamide. Examples include Biktara (bictegravir + tenofovir alafenamide) and Biktarvi (bictegravir + emtricitabine + tenofovir alafenamide) if they become available from other manufacturers. Generic versions of the individual components (emtricitabine, tenofovir alafenamide) are already available and can be combined by a prescriber under a multiple‑drug prescription.

How to check if a generic version has launched
Regularly consult DrugPatentWatch.com or the FDA’s Orange Book. These resources list approved generics and their approval dates. Once a generic Biktarvy is approved, the FDA will release an ANDA approval letter, and the drug will appear in the Orange Book as a “Generic” product.

---

Sources
[1] DrugPatentWatch.com – Generic application status for bictegravir, emtricitabine, and tenofovir alafenamide.